Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Change in Receivables (2016 - 2025)

Apyx Medical's Change in Receivables history spans 15 years, with the latest figure at $3.9 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 33.67% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $1.3 million, down 35.23%, while the annual FY2025 figure was $1.3 million, 35.23% down from the prior year.
  • Change in Receivables reached $3.9 million in Q4 2025 per APYX's latest filing, up from $1.8 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $3.9 million in Q4 2025 to a low of -$3.9 million in Q1 2025.
  • Average Change in Receivables over 5 years is $495500.0, with a median of $529500.0 recorded in 2023.
  • Peak YoY movement for Change in Receivables: surged 1394.85% in 2021, then crashed 261.86% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $1.7 million in 2021, then dropped by 21.81% to $1.4 million in 2022, then grew by 1.99% to $1.4 million in 2023, then surged by 110.85% to $2.9 million in 2024, then soared by 33.67% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Change in Receivables are $3.9 million (Q4 2025), $1.8 million (Q3 2025), and -$471000.0 (Q2 2025).